by Team Small News | Apr 11, 2025 | Aurobindo Pharma, Pharma
Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, has successfully completed a Phase 1 pharmacokinetics study for its investigational bone drug. The study aimed to evaluate the drug’s ability to maintain a stable level in the bloodstream over a prolonged...
by Team Small News | Apr 9, 2025 | Aurobindo Pharma, Pharma, Sun Pharma, Zydus
The US government, under President Donald Trump, has announced plans to impose new tariffs on pharmaceutical imports, which could significantly impact India, the top supplier of generic drugs to the US. The move aims to push pharmaceutical manufacturing back to the...
by Team Small News | Apr 1, 2025 | Aurobindo Pharma, Divi's Laboratories, Pharma, Sun Pharma, Torrent Pharma, Zydus
Citibank has analyzed the potential impact of US tariffs on Indian pharmaceutical companies and has assigned a low probability to such an event. The brokerage firm simulated a 10% tariff scenario and found that companies with a high exposure to US generics, such as... by Team Small News | Mar 15, 2025 | Aurobindo Pharma, Pharma
Aurobindo Pharma, a pharmaceutical company, has terminated its licensing agreement with Hilleman Laboratories Singapore Pte Ltd for the development, manufacturing, and commercialization of a pediatric pentavalent vaccine candidate. The agreement was signed in... by Team Small News | Mar 13, 2025 | Aurobindo Pharma, Pharma
Aurobindo Pharma, a leading drugmaker, is focusing on sustaining profitability and turnover in the face of rising global uncertainties. According to Chief Financial Officer Santhanam Subramanian, the company’s strategy is centered on scale and diversity, with a...